The activity of
omadacycline and comparators when tested against a subset of Streptococcus pneumoniae from US and European regions of a 2014 global surveillance program (304 isolates) are reported. These MIC results were compared to those obtained when testing S. pneumoniae from 2010 surveillance (1,834 isolates). The
omadacycline MIC50/90 for S. pneumoniae (2014) was 0.06/0.06μg/mL, similar to 2010 (MIC50/90, 0.06/0.12μg/mL). The
omadacycline MIC90 (0.06-0.12μg/mL) was similar for the
penicillin-susceptible, -intermediate, -resistant, multidrug-resistance (MDR; ≥3 classes), and
ceftriaxone nonsusceptible subgroups.
Omadacycline MIC90 values were 0.06-0.12μg/mL for S. pneumoniae from the US and Europe. There was a high degree of resistance with
doxycycline,
erythromycin and
trimethoprim-sulfamethoxazole in both US and EU. For
penicillin-resistant S. pneumoniae, resistance to
doxycycline and
tetracycline in US/Europe was 64.2/61.0% and 63.8/60.5%, respectively,
erythromycin 91.2/75.1, and
ceftriaxone 7.3/4.0%. The potent activity of
omadacycline against S. pneumoniae indicates that
omadacycline merits further study in
bacterial pneumonia, especially where MDR may be a concern.